LRP1 derived peptides as a therapeutic strategy in atherosclerosis. Biochemical, in vitro and in vivo studies

MLA

A. Benitez Amaro, et al. “LRP1 Derived Peptides as a Therapeutic Strategy in Atherosclerosis. Biochemical, in Vitro and in Vivo Studies.” Atherosclerosis, vol. 315, Dec. 2020, pp. e3–4. EBSCOhost, https://doi.org/10.1016/j.atherosclerosis.2020.10.025.

APA

A. Benitez Amaro, Teresa Tarragó, Chiara Pallara, Roger Prades, José Luis Sánchez-Quesada, F. Carreras Costa, R. Leta Petracca, Joan Carles Escolà-Gil, V. Llorente Cortes, & D. Vilades Medel. (2020). LRP1 derived peptides as a therapeutic strategy in atherosclerosis. Biochemical, in vitro and in vivo studies. Atherosclerosis, 315, e3–e4. https://doi.org/10.1016/j.atherosclerosis.2020.10.025

Chicago

A. Benitez Amaro, Teresa Tarragó, Chiara Pallara, Roger Prades, José Luis Sánchez-Quesada, F. Carreras Costa, R. Leta Petracca, Joan Carles Escolà-Gil, V. Llorente Cortes, and D. Vilades Medel. 2020. “LRP1 Derived Peptides as a Therapeutic Strategy in Atherosclerosis. Biochemical, in Vitro and in Vivo Studies.” Atherosclerosis 315 (December): e3–4. doi:10.1016/j.atherosclerosis.2020.10.025.